Missed Out on the AI Memory Rally? These 3 Stocks Are Just Getting Started.

The article highlights three AI-memory beneficiaries: Rambus, Lam Research, and Teradyne. Rambus is cited as trading at 48x 2026 earnings with analysts expecting earnings growth of over 19% annually; Lam Research is at 68x 2026 earnings with projected earnings growth of 21% annually; and Teradyne reported 87% year-over-year revenue growth in Q1 2026, with AI driving about 70% of revenue. Overall tone is constructive on the memory and semiconductor equipment cycle, but the piece is primarily investment commentary rather than new company-specific news.

Analysis

This is less a single-name AI trade than a capex supercycle hidden inside the memory stack. The key second-order effect is that the profit pool is migrating upstream and downstream from the headline GPU winners into the “picks and shovels” of memory interface, fab equipment, and test — businesses with cleaner demand visibility and less platform-specific risk. That said, the market is already re-rating the whole chain, so the edge now comes from identifying which bottleneck gets relieved first: if HBM supply expands faster than expected, pricing power can migrate away from component IP owners and back toward the manufacturing/tooling layers.

Among the three, TER has the best operating leverage but also the highest sensitivity to a normalizing memory buildout. Test demand is strongest when node complexity and stack failure rates rise; once yield curves improve, test intensity can flatten even if unit volumes keep growing. RMBS is the highest-quality economic model because royalties scale without equivalent capital intensity, but its valuation leaves less room for multiple expansion and more dependence on sustained attachment rates across a narrow set of memory platforms.

The contrarian issue is that consensus is assuming a straight-line memory supercycle, while semiconductor history says these regimes usually break at the margin when customers over-order and then digest inventory. The most likely reversal catalyst is not AI demand collapsing, but a capacity response from memory producers that compresses spot pricing and delays incremental orders for equipment and test. That would hit LRCX first on bookings sentiment, then TER on utilization assumptions, while RMBS should be the most resilient because license revenue is less exposed to near-term capex timing.

Net: this is a good environment to own the enablers, but not indiscriminately. The better risk/reward is to prefer royalty and process leverage over cyclical peak exposure, and to treat the strongest momentum name as a tactical trade rather than a long-duration compounder.

Key Decisions for Investors

• Long RMBS vs. short TER as a 6-12 month pair trade: own the tollbooth model and fade the more cyclical test multiple; target ~15-20% relative outperformance if memory capex moderates.
• Add LRCX on pullbacks only, with a 3-6 month horizon: best way to express a multi-year memory capacity build, but wait for any 10-15% drawdown to improve entry because booking revisions will likely stay volatile.
• Take profits incrementally in TER after the recent run: keep core exposure only if AI-related revenue momentum remains above 50% of mix; otherwise the stock is vulnerable to a sharp multiple reset if yields improve faster than expected.
• Use a barbell in RMBS and LRCX rather than chasing single-name beta: RMBS for higher-margin, lower-capex exposure; LRCX for operating leverage to the broader buildout.
• Avoid initiating fresh long exposure in the most extended memory names here; the asymmetry has shifted from first derivative momentum to second derivative execution, which usually favors disciplined entries over headline chasing.